temsirolimus

Temsirolimus is a targeted therapy drug and a specific inhibitor of the mammalian target of rapamycin (mTOR) kinase. It is derived from sirolimus (rapamycin) and acts by binding to the intracellular protein FKBP-12, forming a complex that inhibits mTORC1. This inhibition blocks downstream signaling pathways involved in cell proliferation, growth, survival, and angiogenesis. Temsirolimus reduces the synthesis of vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis and promoting cancer cell death[4][6][1]. It is primarily used for advanced renal cell carcinoma but has also been investigated in other cancers such as prostate cancer[4][7]. The drug is administered intravenously.

Brand names

Torisel

Other names

替西莫司西罗莫司酯化物temsirolimus (INN)Temsirolimus (USAN)